[en] The management of melanoma is a typical example of a pluridisciplinary approach, in order to provide the patient with a rapid and adequate treatment plan after the initial diagnosis. Both in the domains of dermatology, pathology and oncology, enormous progress has been made. Recent advances permit a rapid access to diagnostic techniques using teledermoscopy, an improved diagnostic accuracy using dermoscopy, pre-interventional high-frequency ultrasound and optical coherence tomography, a determination of risk factors using immunohistochemistry and genetic analyses on the pathology samples. Furthermore, the development of immunotherapies, in particular the anti-PD1 antibodies, and the directed therapies, therapies permitting an increased number of patients to experience an increased survival with an acceptable tolerance profile in the event of metastatic lesions. This article describes the patient's care pathway, from the initial diagnosis, staging, to an eventual treatment and follow-up. [fr] Le traitement du mélanome est un exemple type de collaboration multidisciplinaire, afin de pouvoir garantir au patient une prise en charge rapide dès le moment de la détection de la lésion. Tant au niveau dermatologique, anatomopathologique et oncologique, d’énormes progrès ont eu lieu ces dernières années. Ils permettent un accès au diagnostic de plus en rapide par la télédermoscopie, une précision diagnostique accrue par la dermoscopie, l’ultrason à haute fréquence et la tomographie par cohérence optique, une détermination des facteurs de risque immunohistochimiques et génétiques sur les analyses anatomo-pathologiques ainsi que le recours à des immunothérapies, notamment les anti-PD1, et à des traitements ciblés. Ces nouveaux traitements permettent souvent une plus longue survie du patient, avec un profil de tolérance acceptable en cas de lésions métastatiques. Cet article reprend le trajet de soins du patient, du diagnostic initial et du staging au traitement éventuel avec son suivi.
Disciplines :
Dermatology Laboratory medicine & medical technology
Author, co-author :
Absil, Gilles ; Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie
DAMSIN, Thomas ; Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie
LEBAS, Eve ; Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie
Libon, Florence ; Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie
SOMJA, Joan ; Centre Hospitalier Universitaire de Liège - CHU > > Service dermatopathologie
COLLINS, Patrick ; Centre Hospitalier Universitaire de Liège - CHU > > Service dermatopathologie
REGINSTER, Marie-Annick ; Centre Hospitalier Universitaire de Liège - CHU > > Service dermatopathologie
QUATRESOOZ, Pascale ; Centre Hospitalier Universitaire de Liège - CHU > > Service dermatopathologie
RORIVE, Andrée ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
MARCHAL, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
JACQUEMIN, Denise ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chirurgie plastique et maxillo-faciale
BOUS, Aurélie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chirurgie plastique et maxillo-faciale
PIRET, Pascal ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de radiothérapie
NIKKELS, Arjen ; Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie
Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo 2014;28:1005-11.
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018;103:356-87.
Uhoda I, Quatresooz P, Fumal I, et al. Updating trends in cutaneous cancers in south-east Belgium. Oncol Rep 2004;12:111-4.
Nikkels AF, Nikkels-Tassoudji N, Jerusalem-Noury E, et al. Skin cancer screening campaign in the German speaking Community of Belgium. Acta Clin Belg 2004;59:194-8.
Suppa M, Gandini S, Njimi H, et al. Association of sunbed use with skin cancer risk factors in Europe: an investigation within the Euromelanoma skin cancer prevention campaign. J Eur Acad Dermatol Venereol 2019;33 Suppl 2:76-88.
Damsin T, Canivet G, Jacquemin P, et al. Value of teledermoscopy in primary healthcare centers: Preliminary results of the TELESPOT project in Belgium. Dermatol Ther 2020;10:1405-13.
Damsin T, Jacquemin P, Canivet G, et al. TELESPOT Project: early detection of melanoma by teledermoscopy in general practice. Rev Med Liege 2019;74:650-4.
Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017;9:34.
Rosendahl CO, Grant-Kels JM, Que SK. Dysplastic nevus: fact and fiction. J Am Acad Dermatol 2015;73:507-12.
Nikkels AF. Le mélanome: du diagnostic clinique à la dermoscopie digitalisée. Académie Royale Belge de Médecine 2012. En ligne: http://tiny.cc/youtubeARMB, dernière consultation le 2/03/2021.
Argenziano G, Giacomel J, Zalaudek I, et al. A clinico-dermoscopic approach for skin cancer screening: recommendations involving a survey of the International Dermoscopy Society. Dermatol Clin 2013;31:525-34.
Detrixhe A, Libon F, Mansuy M, et al. Melanoma masquerading as nonmelanocytic lesions. Melanoma Res 2016;26:631-4.
de la Fouchardiere A, Blokx W, van Kempen LC, et al. EURACAN. ESP, EORTC, and EURACAN Expert Opinion: practical recommendations for the pathological diagnosis and clinical management of intermediate melanocytic tumors and rare related melanoma variants. Virchows Arch 2021. doi: 10.1007/ s00428-020-03005-1.
Cho-Vega JH. A diagnostic algorithm for atypical spitzoid tumors: guidelines for immunohistochemical and molecular assessment. Mod Pathol 2016;29:656-70.
Kim A, Cohen MS. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. Expert Opin Drug Discov 2016;11:907-16.
National Comprehensive Cancer Network (NCCN). Melanoma: cutaneous. En ligne: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf, dernière consultation le 2/03/2021.
Falk Delgado A, Zommorodi S, Falk Delgado A. Sentinel lymph node biopsy and complete lymph node dissection for melanoma. Curr Oncol Rep 2019;21:54.
Abel Gonzalez. Sentinel lymph node biopsy: Past and present implications for the management of cutaneous melanoma with nodal metastasis. Am J Clin Dermatol 2018;19 (Suppl 1):24-30.
Michielin O, van Akkooi A, Ascierto P, et al. Cutaneous melanoma: ESMO clinical practice guidelines. Ann Oncol 2019;30:1884-901.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017;377:1345-56.
Jansen YJL, Rozeman EA, Mason R, et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol 2019;30:1154-61.
Lui P, Cashin R, Machado M, et al. Treatments for metastatic melanoma: Synthesis of evidence from randomized trials. Cancer Treat Rev 2007;33:665-80.
Wernicke AG, Polce S, Parashar B. Role of radiation in the era of effective systemic therapy for melanoma. Surg Clin North Am 2020;100:189-99.
D’Andrea MA, Reddy GK. Systemic antitumor effects and abscopal responses in melanoma patients receiving radiation therapy. Oncology 2020;98:202-15.
Primiero CA, McInerney-Leo AM, Betz-Stablein B, et al. Evaluation of the efficacy of 3D total-body photography with sequential digital dermoscopy in a high-risk melanoma cohort: protocol for a randomised controlled trial. BMJ Open 2019;9:e032969.
Libon F, Cavalier E, Nikkels AF. La vitamine D et la peau. Rev Med Liege 2013;68:458-64.
De Smedt J, Van Kelst S, Boecxstaens V, et al. Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial. BMC Cancer 2017;17:562.
